Alpha-glucosidase Inhibitors Market Size
| Study Period | 2018 - 2029 |
| Market Size (2024) | USD 4.76 Billion |
| Market Size (2029) | USD 5.30 Billion |
| CAGR (2024 - 2029) | 2.17 % |
| Fastest Growing Market | Middle East and Africa |
| Largest Market | Asia Pacific |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Alpha-glucosidase Inhibitors Market Analysis
The Alpha-glucosidase Inhibitors Market size is estimated at USD 4.76 billion in 2024, and is expected to reach USD 5.30 billion by 2029, growing at a CAGR of 2.17% during the forecast period (2024-2029).
Alpha-glucosidase inhibitors are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of carbohydrates. Carbohydrates are converted into monosaccharides by alpha-glucosidase enzymes present in cells lining the intestine, enabling monosaccharides to be absorbed through the intestine. Hence, alpha-glucosidase inhibitors reduce the impact of dietary carbohydrates on blood sugar.
Alpha-glucosidase inhibitors are used to establish greater glycemic control over hyperglycemia in diabetes mellitus type 2, they may be used as monotherapy in conjunction with an appropriate diabetic diet and exercise, or they may be used in conjunction with other anti-diabetic drugs. Therefore, they have been potential candidates for treating patients affected by COVID-19 infection, with or even without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times.
73 million adults were living with diabetes in the IDF MENA Region, which is estimated to increase to 95 million by 2030. 48 million adults in the IDF MENA Region are living with Impaired Glucose Tolerance, which increases their risk of developing type 2 diabetes.
The World Health Assembly agreed on a Resolution on strengthening the prevention and control of diabetes. It recommends action in areas including increasing access to medicines and health products for the treatment of diabetes and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to the transparency of markets for diabetes medicines and health products.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Alpha-glucosidase Inhibitors Market Trends
Rising diabetes prevalence globally
The diabetes population globally is expected to rise by 1.9% over the forecast period.
According to International Diabetes Federation, the adult diabetes population was approximately 537 million, which will increase by 643 million in 2030. Obesity is considered one of the major factors contributing to the disease, primarily Type 2 diabetes. Continued elevation in blood glucose levels in diabetes patients can contribute to progressive complications such as renal, nerve, and ocular damage.
Type 2 diabetes is increasingly prevalent and associated with an increased cardiovascular and renal disease risk. Alpha-glucosidase inhibitors may also be used in patients with impaired glucose tolerance and delay the occurrence of type 2 diabetes mellitus in these patients. They are particularly useful for patients at risk of hypoglycemia or lactic acidosis and are unsuitable candidates for other antidiabetic drugs such as sulfonylureas and metformin. Alpha-glucosidase inhibitors are FDA approved for the treatment of type 2 diabetes mellitus.
WHO launched the Global Diabetes Compact, a global initiative to improve diabetes prevention and care, focusing on supporting low and middle-income countries. The Compact is bringing together national governments, UN organizations, nongovernmental organizations, private sector entities, academic institutions, philanthropic foundations, people living with diabetes, and international donors. The Compact aims to work on a shared vision of reducing the risk of diabetes and ensuring that all people diagnosed with diabetes can access equitable, comprehensive, affordable, and quality treatment and care.
Therefore, the studied market is anticipated to grow over the analysis period due to increased prevalence and the above factors.
Middle East and Africa is expected to register the highest CAGR in Alpha-glucosidase Inhibitors Market over the forecast period
Over the forecast period, the Middle East and Africa region is expected to witness a CAGR of more than 3.6%.
Acarbose (Precose), Voglibose, and miglitol (Glyset) are medications in Alpha-glucosidase inhibitors class of drugs. These drugs help keep the amount of glucose in the blood from rising too fast after meals. Alpha-glucosidase inhibitors help lower postprandial diabetes. These medications reduce glycosylated hemoglobin levels and lower the postprandial insulin concentration. Regulation of post-meal hyperglycemia is vital as it is associated with the development of complications and also increases the risk of heart problems.
The Government is working on plans and policies to control the outcomes of diabetes. For instance, in July 2022, Saudi Government announced that Saudi Arabia saw a growing demand for quality healthcare services spurred by changes. It includes an increasing aging population and a growing prevalence of lifestyle diseases such as diabetes and obesity. The Government and private sector are involved in working on healthcare entities, certifications, and regulations. The Government is taking steps to include 100% of Saudi citizens covered by insurance. They are also working towards ensuring affordability, access, quality digital healthcare, and primary care with cost-effectiveness.
The market is expected to grow during the forecast period due to the factors above.
Alpha-glucosidase Inhibitors Industry Overview
The Alpha-glucosidase Inhibitors Market studied is highly fragmented, consisting of major manufacturers like Bayer, SunPharma, Pfizer, Takeda, and Zydus, holding a global market presence, and other region-specific manufacturers.
Alpha-glucosidase Inhibitors Market Leaders
-
Sun Pharma
-
Bayer
-
Takeda
-
Torrent Pharmaceuticals
-
Pfizer Inc.
*Disclaimer: Major Players sorted in no particular order
Alpha-glucosidase Inhibitors Market News
- January 2023: The Indian Drug pricing regulator National Pharmaceutical Pricing Authority (NPPA) fixed the retail price of 12 scheduled formulations under the Drugs (Prices Control) Order, 2013 (NLEM 2022). The retail price of one tablet of anti-diabetes combination drug Glimepiride, Voglibose & Metformin (extended-release) is fixed at INR 13.83 (USD 0.17).
- May 2022: US FDA issued a revised draft guidance for the industry on generic acarbose recommending in vitro comparative dissolution studies or one in vivo pilot bioequivalence study and one in vivo pivotal bioequivalence study with pharmacodynamic endpoints studies.
Alpha-glucosidase Inhibitors Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
- 5.1 Alpha-glucosidase Inhibitors
-
5.2 Geography
- 5.2.1 North America
- 5.2.1.1 United States
- 5.2.1.2 Canada
- 5.2.1.3 Rest of North America
- 5.2.2 Europe
- 5.2.2.1 France
- 5.2.2.2 Germany
- 5.2.2.3 Italy
- 5.2.2.4 Spain
- 5.2.2.5 United Kingdom
- 5.2.2.6 Russia
- 5.2.2.7 Rest of Europe
- 5.2.3 Latin America
- 5.2.3.1 Mexico
- 5.2.3.2 Brazil
- 5.2.3.3 Rest of Latin America
- 5.2.4 Asia-Pacific
- 5.2.4.1 Japan
- 5.2.4.2 South Korea
- 5.2.4.3 China
- 5.2.4.4 India
- 5.2.4.5 Australia
- 5.2.4.6 Vietnam
- 5.2.4.7 Malaysia
- 5.2.4.8 Indonesia
- 5.2.4.9 Philippines
- 5.2.4.10 Thailand
- 5.2.4.11 Rest of Asia-Pacific
- 5.2.5 Middle East and Africa
- 5.2.5.1 Saudi Arabia
- 5.2.5.2 Iran
- 5.2.5.3 Egypt
- 5.2.5.4 Oman
- 5.2.5.5 South Africa
- 5.2.5.6 Rest of Middle East and Africa
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes population
- 6.2 Type-2 Diabetes population
7. COMPETITIVE LANDSCAPE
-
7.1 Company Profiles
- 7.1.1 Bayer
- 7.1.2 Takeda
- 7.1.3 Pfizer
- 7.1.4 Glenmark
- 7.1.5 Sun Pharma
- 7.1.6 Torrent
- 7.1.7 Unichem
- 7.1.8 Hexalag
- 7.1.9 Eris
- 7.1.10 Blue Cross
- *List Not Exhaustive
- 7.2 Company Share Analysis
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAlpha-glucosidase Inhibitors Industry Segmentation
Alpha-glucosidase inhibitors are a class of drugs used in treating type 2 diabetes mellitus alone or combined with other antidiabetic drugs that are particularly useful for reducing postprandial hyperglycemia. The Alpha-glucosidase Inhibitors Market is segmented into Geography. The report offers the value (in USD) and volume (in Units) for the above segments.
| Geography | North America | United States |
| Canada | ||
| Rest of North America | ||
| Geography | Europe | France |
| Germany | ||
| Italy | ||
| Spain | ||
| United Kingdom | ||
| Russia | ||
| Rest of Europe | ||
| Geography | Latin America | Mexico |
| Brazil | ||
| Rest of Latin America | ||
| Geography | Asia-Pacific | Japan |
| South Korea | ||
| China | ||
| India | ||
| Australia | ||
| Vietnam | ||
| Malaysia | ||
| Indonesia | ||
| Philippines | ||
| Thailand | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | Saudi Arabia |
| Iran | ||
| Egypt | ||
| Oman | ||
| South Africa | ||
| Rest of Middle East and Africa |
Alpha-glucosidase Inhibitors Market Research FAQs
How big is the Alpha-glucosidase Inhibitors Market?
The Alpha-glucosidase Inhibitors Market size is expected to reach USD 4.76 billion in 2024 and grow at a CAGR of 2.17% to reach USD 5.30 billion by 2029.
What is the current Alpha-glucosidase Inhibitors Market size?
In 2024, the Alpha-glucosidase Inhibitors Market size is expected to reach USD 4.76 billion.
Who are the key players in Alpha-glucosidase Inhibitors Market?
Sun Pharma, Bayer, Takeda, Torrent Pharmaceuticals and Pfizer Inc. are the major companies operating in the Alpha-glucosidase Inhibitors Market.
Which is the fastest growing region in Alpha-glucosidase Inhibitors Market?
Middle East and Africa is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Alpha-glucosidase Inhibitors Market?
In 2024, the Asia Pacific accounts for the largest market share in Alpha-glucosidase Inhibitors Market.
What years does this Alpha-glucosidase Inhibitors Market cover, and what was the market size in 2023?
In 2023, the Alpha-glucosidase Inhibitors Market size was estimated at USD 4.66 billion. The report covers the Alpha-glucosidase Inhibitors Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Alpha-glucosidase Inhibitors Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Alpha Glucosidase Inhibitors Industry Report
Statistics for the 2024 Alpha Glucosidase Inhibitors market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Alpha Glucosidase Inhibitors analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
